The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.
Original Article: TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC